Quest Laborato.

Why is Quest Laboratories Ltd falling/rising?

As of 10-Jun, Quest Laboratories Ltd's stock price is rising to 100.00, driven by strong fundamentals, increased investor participation, and outperformance relative to its sector. Despite trading below moving averages, the company's high ROE and low debt-to-equity ratio indicate financial health and confidence in its growth prospects.

As of 10-Jun, Quest Laboratories Ltd's stock price is rising, currently at 100.00, reflecting a change of 1.0 (1.01%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.47% today, indicating a positive performance relative to its peers. Additionally, there has been a notable rise in investor participation, with delivery volume increasing by 11.73% against the 5-day average, suggesting growing interest among investors.<BR><BR>Despite the stock trading lower than its moving averages over various periods, the company's fundamentals remain strong. Quest Laboratories boasts a high management efficiency with a return on equity (ROE) of 25.90% and a low debt-to-equity ratio of 0.09 times, which are indicators of financial health. Furthermore, the company has demonstrated healthy long-term growth, with operating profit increasing at an annual rate of 30.53%. <BR><BR>The stock's performance over the past year has also been impressive, generating a return of 16.41% while the broader market has faced negative returns. This market-beating performance, coupled with an increase in institutional investor participation—where institutional investors have raised their stake by 0.67%—suggests confidence in the company's future prospects. Overall, these factors contribute to the stock's upward movement.

What does Quest Laborato. do?

Quest Laboratories Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 32 Cr and a net profit of 3 Cr for the quarter ending March 2026. It has a market cap of INR 162 Cr and a P/E ratio of 11.00.

Overview:<BR>Quest Laboratories Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1998 as "Quest Laboratories Private Limited" and later changed its status to a Public Limited company, adopting the name "Quest Laboratories Limited" in January 2024. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 32 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 3 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 162 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 11.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.19 <BR>Return on Equity: 16.70% <BR>Price to Book: 1.80 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Which are the latest news on Quest Laborato.?

How big is Quest Laborato.?

As of 10th June, Quest Laboratories Ltd has a market capitalization of 162.00 Cr, with net sales of 111.81 Cr and a net profit of 15.02 Cr reported in the latest four quarters.

As of 10th June, Quest Laboratories Ltd has a market capitalization of 162.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Quest Laboratories reported Net Sales of 111.81 Cr and a Net Profit of 15.02 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 81.80 Cr and Total Assets of 121.65 Cr.

Should I buy, sell or hold Quest Laboratories Ltd?

Are Quest Laboratories Ltd latest results good or bad?

Quest Laboratories Ltd's latest results show strong revenue growth of 68% year-on-year, reaching ₹25.62 crores, but a significant decline in net profit by 33.66% and a drop in operating margin to 13.23% indicate serious profitability concerns, suggesting the overall results are more negative than positive.

Quest Laboratories Ltd's latest results present a mixed picture. On one hand, the company achieved a notable revenue growth of 68.00% year-on-year, with net sales reaching ₹25.62 crores. This indicates strong market demand and effective expansion of its product portfolio. However, this impressive topline growth is overshadowed by significant profitability concerns. <BR><BR>Net profit for the quarter was ₹4.02 crores, which reflects a concerning decline of 33.66% compared to the same quarter last year. Additionally, the operating margin has sharply decreased to 13.23%, down from 32.15% a year ago, indicating that rising costs are eroding profitability despite increased sales. <BR><BR>The stock is currently trading below its key moving averages and has underperformed relative to its peers and the broader market, raising concerns about investor sentiment and future growth prospects. Overall, while the revenue growth is a positive sign, the decline in profitability and margins suggests that the results are more negative than positive, highlighting challenges that the company needs to address moving forward.

How has been the historical performance of Quest Laborato.?

Quest Laborato has shown significant growth from Mar'23 to Mar'25, with net sales increasing from 0.62 Cr to 103.91 Cr and profit after tax rising from 0.05 Cr to 13.57 Cr, despite a negative cash flow of -23.00 Cr in Mar'25. Total assets also grew from 46.94 Cr to 121.65 Cr during this period.

Answer:<BR>The historical performance of Quest Laborato shows significant growth in various financial metrics over the past few years.<BR><BR>Breakdown:<BR>Quest Laborato's net sales have increased from 0.62 Cr in Mar'23 to 103.91 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 0.62 Cr in Mar'23 to 103.91 Cr in Mar'25. The company's total expenditure, excluding depreciation, also rose from 0.53 Cr in Mar'23 to 87.93 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) grew from 0.09 Cr in Mar'23 to 20.22 Cr in Mar'25, showcasing improved profitability, while profit before tax increased from 0.07 Cr in Mar'23 to 18.68 Cr in Mar'25. Profit after tax also saw a substantial rise from 0.05 Cr in Mar'23 to 13.57 Cr in Mar'25. On the balance sheet, total assets grew from 46.94 Cr in Mar'23 to 121.65 Cr in Mar'25, with total liabilities increasing from 46.94 Cr to 30.26 Cr in the same period. The cash flow from operating activities turned negative at -23.00 Cr in Mar'25, contrasting with positive cash flows in previous years. Overall, Quest Laborato has demonstrated robust growth in revenue and profitability, despite challenges in cash flow management.

Is Quest Laborato. overvalued or undervalued?

As of September 16, 2025, Quest Laboratories is considered very attractive and undervalued with a PE ratio of 11.35 and strong financial metrics, despite a year-to-date stock decline of 21.27% compared to a 6.74% gain in the Sensex.

As of 16 September 2025, the valuation grade for Quest Laboratories has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, especially when considering its key financial ratios. The PE ratio stands at 11.35, while the EV to EBITDA is 8.47, and the ROCE is a strong 24.38%, showcasing efficient capital utilization.<BR><BR>In comparison to its peers, Quest Laboratories appears favorably positioned. For instance, Sun Pharma has a PE ratio of 33.64, categorizing it as expensive, while Cipla, deemed attractive, has a PE of 23.31. The PEG ratio for Quest is notably at 0.00, suggesting that it may be undervalued relative to its growth potential. Despite recent stock performance lagging behind the Sensex, with a year-to-date decline of 21.27% compared to a 6.74% gain in the index, the underlying financial metrics support a bullish outlook for Quest Laboratories.

What is the technical trend for Quest?

As of May 29, 2025, Quest's technical trend has shifted to bearish, supported by negative indicators from the MACD, Bollinger Bands, and moving averages, with no immediate reversal signals evident.

As of 29 May 2025, the technical trend for Quest has changed from mildly bearish to bearish. The current stance is bearish with a strong indication of weakness. The weekly MACD is bearish, and the Bollinger Bands also reflect a bearish trend. Daily moving averages confirm the bearish outlook. The KST on a weekly basis is bearish as well. Overall, the lack of significant signals from the RSI, Dow Theory, and OBV suggests a continuation of the bearish trend without any immediate reversal signals.

Who are the top shareholders of the Quest?

The top shareholder of Quest is Anil Kumar Sabarwal, holding 62.29% of the shares, with individual investors owning 24.35% and three foreign institutional investors holding a combined 0.95%. The highest public shareholder is Priti Kamlesh Gandhi, who owns 1.22%.

The top shareholders of Quest include the promoters, with Anil Kumar Sabarwal holding the largest share at 62.29%. There are no pledged promoter holdings, and individual investors collectively hold 24.35% of the shares. Additionally, there are three foreign institutional investors (FIIs) that hold a combined 0.95%. The highest public shareholder is Priti Kamlesh Gandhi, who owns 1.22%.

When is the next results date for Quest?

No Upcoming Board Meetings

Has Quest declared dividend?

No Dividend History Available

Who are the peers of the Quest?

Quest's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Sun Pharma and Cipla show excellent management and growth, while Divi's Lab has the highest 1-year return at 51.96%, and Quest's return is 0.00%.

Peers: The peers of Quest are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, BDH Industries, Tyche Industries, Lactose (India), Sotac Pharma., and Vaishali Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Below Average management risk is found at Lactose (India), Sotac Pharma., Vaishali Pharma, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, BDH Industries, Tyche Industries, Lactose (India), Vaishali Pharma, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, BDH Industries, Tyche Industries, while Below Average capital structure is noted for Lactose (India), Sotac Pharma., Vaishali Pharma, and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while BDH Industries has the lowest at -25.45%. Quest's own 1-year return is 0.00%, which is lower than both of these peers. Additionally, Lactose (India), BDH Industries, Tyche Industries, and Vaishali Pharma have negative six-month returns.